US45257U1088
© BusinessWire
15.12.2025
IMNM
LISTED
NASDAQ
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoi...
Themefolio
Profiler
Peergroup
© BusinessWire
14.12.2025
IMNM
LISTED
NASDAQ
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an in...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
25.11.2025
IMNM
LISTED
NASDAQ
Immunome to Present at Upcoming Investor Conferences
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management will participate in the following investor conferences:
Piper Sandler 37th Annual Healthcare Conference
Presentation Date/Time: December 3, 2025, at 9 a.m....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.11.2025
IMNM
LISTED
NASDAQ
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and provided a business update.
“Immunome’s pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock optio...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
IMNM
LISTED
NASDAQ
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET.
Interested parties can access the live audio webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
IMNM
LISTED
NASDAQ
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity.
HC74 is...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Oct. 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opti...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
IMNM
LISTED
NASDAQ
Infinimmune Announces Research Collaboration with Immunome
News Preview
Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced a research collaboration agreement with Immunome, Inc. (NASDAQ: IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed.
Inf...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opt...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
IMNM
LISTED
NASDAQ
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, Sept. 9, 2025 at 1:00 p.m. Eastern Time.
Interested parties can access the live...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
01.08.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opti...
Themefolio
Profiler
Peergroup
© BusinessWire
03.07.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opti...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opti...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
IMNM
LISTED
NASDAQ
Immunome to Present at Upcoming Investor Conferences
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences:
TD Cowen 6th Annual Oncology Innovation Summit
Presentation Date/Time: May 27, 2025, 6:30 a.m. - 7:00 a.m. PT
Goldman Sachs 46th...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
IMNM
LISTED
NASDAQ
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update.
“Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock optio...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
IMNM
LISTED
NASDAQ
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time.
Interested parties ca...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opt...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
IMNM
LISTED
NASDAQ
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update.
“Immunome’s efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegal...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
IMNM
LISTED
NASDAQ
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC.
“Immunome is developing differentiated ADCs that we believe can greatly benefit cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock opt...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
IMNM
LISTED
NASDAQ
Immunome to Present at Upcoming March Conferences
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025:
TD Cowen 45th Annual Health Care Conference
Conference Dates: March 3-5, 2025
Presentation Date/Time: March 4, 2025,...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
IMNM
LISTED
NASDAQ
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
News Preview
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
IMNM
LISTED
NASDAQ
Immunome Announces Pricing of Upsized Public Offering of Common Stock
News Preview
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome.
Th...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
IMNM
LISTED
NASDAQ
Immunome Announces Proposed Public Offering of Common Stock
News Preview
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million of shares of its common stock. All of the shares are be...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
IMNM
LISTED
NASDAQ
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT.
Interested parties can...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock o...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
IMNM
LISTED
NASDAQ
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time.
Interested parties c...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
IMNM
LISTED
NASDAQ
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
“Immunome continues to advance its pipeline,” said Clay B. Siegall, Ph.D., President a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
IMNM
LISTED
NASDAQ
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
IMNM
LISTED
NASDAQ
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled “Preclinical evaluation of IM-1021, a ROR1-targeted antib...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
IMNM
LISTED
NASDAQ
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Th...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
IMNM
LISTED
NASDAQ
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology an...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock op...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2024
IMNM
LISTED
NASDAQ
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
IMNM
LISTED
NASDAQ
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P....
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
IMNM
LISTED
NASDAQ
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
“Immunome is focused on establishing and developing a broad pipeline of differentiated onc...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
